Switching to exemestane after 2–3 years of adjuvant tamoxifen prolongs disease-free survival, but not overall survival, in postmenopausal women surviving primary breast cancer, compared with continuous tamoxifen
Year: 2004
Type: article
Source: Cancer Treatment Reviews
Author: Christina Davies
Institution: University of Oxford
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2120638533
